Clinical measurement in drug evaluation
著者
書誌事項
Clinical measurement in drug evaluation
John Wiley & Sons, 1995
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Proceedings of a symposium held in Edinburgh in Oct. 1993 sponsored by Inveresk Clinical Research
Includes bibliographical references and index
内容説明・目次
内容説明
Internationally renowned authorities from diverse fields present the principles and practice regarding the measurement of drug effects in humans and its role in the analysis and development of new chemical entities. The main thrust is on surrogate endpoints, peripheral vascular disease, the reliability of data collection and interpretation as well as the identification, predictability and performance of drug interactions and adverse effects.
目次
Contributors.
Preface.
SURROGATE ENDPOINTS AS A MEASURE OF DRUG EFFECTS.
A Regulatory Authority's Opinion About Surrogate Endpoints (R.Temple).
What to Measure in Dementia (L. Whalley & S. Gerhand).
Twenty-foour-hour ambulatory arterial (blood) pressuremeasurement and the assessment of antihypertensive drug efficacy(J. Hasford, W. Meister).
Potential Measurements in Patients with Osteoporosis (C.Miller).
Are bronchial challenge studies indicators of antiasthmaticactivity? (A. J. Frew, S. T. Holgate)
DRUGS AFFECTING BLOOD FLOW TO THE PERIPHERAL CIRCULATION.
Measurements of Blood Rheology for the Evaluation ofPharmacological Agents (G. Nash).
Platelet Function Tests (P. Wyld).
Assessment of the Effects of Drugs on the Peripheral Vasculature(D. Webb & M. Hand).
PRECISION, VALIDITY AND REPRODUCIBILITY OF MEASUREMENT.
Bias and Confounding in Clinical Studies (D. Jones).
What Does Good Clinical Practice Have to Say About ClinicalMeasurement? (E. Hvidberg).
Measurement of bioequivalence and its relevance to tthe clinicalsituation (T. Salmonson)
The 'Clinical Trial' of the Clinical Trial (A. Feinstein).
Patient compliancewith prescribed drug regimens: overview of thepast 30 yers of research (j. Urguhart).
MEASUREMENT OF ADVERSE EVENTS.
Prediction of drug interactions: implications of recent advancesin drug metabolism (G. T. Tucker).
What number of patients is necessary to establish drug safety?(P. R. Jackson, E. J. Wallis, W. w. Yeo, L E. Ramsay)
Accuracy of adverse data from post-marketing studies and theinfluence on extension of licensed indications (D. H.Lawson).
Controlled Clinical Trials: Contribution to Drug Safety (M.Langman).
Predicting Adverse Drug Reactions (C. George).
THE EDINBURGH DRUG ABSORPTION FOUNDATION LECTURE.
Interactions in First-Pass Metabolism and Variability in DrugResponse (P. Neuvonen).
Index.
「Nielsen BookData」 より